News | December 30, 2025
Italfarmaco and JCR Pharmaceuticals partner to bring Duchenne therapy to Japan
The partnership also sets the stage for broader collaboration on rare disease treatments
The partnership also sets the stage for broader collaboration on rare disease treatments
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
Full approval will depend on verification of clinical benefit in a confirmatory trial
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
NUFYMCO BLA has been approved by the USFDA
The company also reported significant progress toward its internally defined Sustainable Development Goals
Subscribe To Our Newsletter & Stay Updated
